ABSTRACT:

Renal failure is a serious condition, with the loss of kidney function being irreversible and frequently managed by dialysis or kidney transplant. Hyperlipidemia is a prevalent condition among CKD patients, particularly affecting those with associated comorbidities such as T2DM. This literature review presents an integration of current research findings on the relationship between hyperlipidemia and renal failure with particular attention to cardiovascular complications and patterns of dyslipidemia in this population. The accurate comprehension of these interrelations is the key to advancing clinical outcomes in terms of developing efficient strategies of control. This literature review synthesizes current research findings about dyslipidemia in patients with renal failure, identifies the knowledge gaps, and recommends directions for further research.

REFERENCES :

1) Ahmadmehrabi, S.., & Tang, W.. (2018). Hemodialysis‐induced cardiovascular disease. Seminars in Dialysis , 31 , 258 – 267 . http://doi.org/10.1111/sdi.12694
2) Angeli, J.., Schneider, Manuela., Proneth, B.., Tyurina, Y.., Tyurin, V.., Hammond, V.., Herbach, N.., Aichler, M.., Walch, A.., Eggenhofer, E.., Basavarajappa, D.., Rådmark, O.., Kobayashi, Sho., Seibt, Tobias., Beck, H.., Neff, F.., Esposito, I.., Wanke, R.., Förster, H.., Yefremova, Olena., Heinrichmeyer, Marc., Bornkamm, G.., Geissler, E.., Thomas, Stephen B.., Stockwell, B.., O’Donnell, V.., Kagan, V.., Schick, Joel A.., & Conrad, M.. (2014). Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nature Cell Biology , 16 , 1180-1191 . http://doi.org/10.1038/ncb3064
3) Arnold, S.., Hunt, P.., Chen, H.., Maclachlan, S.., Repetto, E.., Vora, J.., & Kosiborod, M.. (2018). Cardiovascular Outcomes and Mortality in Type 2 Diabetes with Associated Cardio-Renal-Metabolic Comorbidities. Diabetes . http://doi.org/10.2337/DB18-1582-P
4) Baigent, C.., Landray, M.., Reith, C.., Emberson, J.., Wheeler, D.., Tomson, C.., Wanner, C.., Krane, V.., Cass, A.., Craig, J.., Neal, B.., Jiang, Lixin., Hooi, L.., Levin, A.., Agodoa, L.., Gaziano, M.., Kasiske, B.., Walker, R.., Massy, Z.., Feldt-Rasmussen, B.., Krairittichai, U.., Ophascharoensuk, V.., Fellström, B.., Holdaas, H.., Tesar, V.., Więcek, A.., Grobbee, D.., Zeeuw, D. de., Grönhagen‐Riska, C.., Dasgupta, T.., Lewis, D.., Herrington, W.., Mafham, M.., Majoni, W.., Wallendszus, K.., Grimm, R.., Pedersen, T.., Tobert, J.., Armitage, J.., Baxter, A.., Bray, C.., Chen, Yiping., Chen, Zhengming., Hill, M.., Knott, C.., Parish, S.., Simpson, D.., Sleight, P.., Young, A.., & Collins, R.. (2011). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet , 377 , 2181 – 2192 . http://doi.org/10.1016/S0140-6736(11)60739-3
5) Becker, M.., Schumacher, H.., Espinoza, L.., Wells, A.., Macdonald, P.., Lloyd, E.., & Lademacher, C.. (2010). The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research & Therapy , 12 , R63 – R63 . http://doi.org/10.1186/ar2978
6) Bendz, H.., Schön, S.., Attman, P.., & Aurell, M.. (2010). Renal failure occurs in chronic lithium treatment but is uncommon.. Kidney international , 77 3 , 219-24 . http://doi.org/10.1038/ki.2009.433
7) Brautbar, A.., & Ballantyne, C.. (2011). Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nature Reviews Cardiology , 8 , 253-265 . http://doi.org/10.1038/nrcardio.2011.2
8) Cass, A.. (2010). Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.. American heart journal , 160 5 , 785-794.e10 . http://doi.org/10.1016/j.ahj.2010.08.012
9) Chang, Ming., Yu, Zhigang., Shenker, A.., Wang, Jessie., Pursley, J.., Byon, W.., Boyd, R.., LaCreta, F.., & Frost, C.. (2016). Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. The Journal of Clinical Pharmacology , 56 . http://doi.org/10.1002/jcph.633
10) Chen, Yue-Ren., Yang, Yu., Wang, Shu-Chuan., Chiu, P.., Chou, W.., Lin, Ching-Yuang., Chang, Jer-Ming., Chen, T.., Ferng, S.., & Lin, Chun-Liang. (2013). Effectiveness of multidisciplinary care for chronic kidney disease in Taiwan: a 3-year prospective cohort study.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association , 28 3 , 671-82 . http://doi.org/10.1093/ndt/gfs469
11) Chung, K.., Lee, E.., Lee, Mi Kyung., Oh, G.., Yu, B.., & Chung, H.. (2018). Impairment of PPARα and the Fatty Acid Oxidation Pathway Aggravates Renal Fibrosis during Aging.. Journal of the American Society of Nephrology : JASN , 29 4 , 1223-1237 . http://doi.org/10.1681/ASN.2017070802
12) Damman, K.., Valente, M.., Voors, A.., O’connor, C.., Veldhuisen, D. V. van., & Hillege, H.. (2014). Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis.. European heart journal , 35 7 , 455-69 . http://doi.org/10.1093/eurheartj/eht386
13) Davies, M.., Bain, S.., Atkin, S.., Rossing, P.., Scott, D.., Shamkhalova, M.., Bosch‐Traberg, H.., Syrén, A.., & Umpierrez, G.. (2015). Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care , 39 , 222 – 230 . http://doi.org/10.2337/dc14-2883
14) Dimopoulos, M.., Sonneveld, P.., Leung, N.., Merlini, G.., Ludwig, H.., Kastritis, E.., Goldschmidt, H.., Joshua, D.., Orlowski, R.., Powles, R.., Vesole, D.., Garderet, L.., Einsele, H.., Palumbo, A.., Cavo, M.., Richardson, P.., Moreau, P.., Miguel, J. S. San., Rajkumar, S.., Durie, B.., & Terpos, E.. (2016). International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 34 13 , 1544-57 . http://doi.org/10.1200/JCO.2015.65.0044
15) Etgen, T.., Sander, D.., Bickel, H.., & Förstl, Hans. (2011). Mild cognitive impairment and dementia: the importance of modifiable risk factors.. Deutsches Arzteblatt international , 108 44 , 743-50 . http://doi.org/10.3238/arztebl.2011.0743
16) Ferro, C.., Mark, P.., Kanbay, M.., Sarafidis, P.., Heine, G.., Rossignol, P.., Massy, Z.., Mallamaci, F.., Valdivielso, J.., Małyszko, J.., Verhaar, M.., Ekart, R.., Vanholder, R.., London, G.., Ortiz, A.., & Zoccali, C.. (2018). Lipid management in patients with chronic kidney disease. Nature Reviews Nephrology , 14 , 727-749 . http://doi.org/10.1038/s41581-018-0072-9
17) Ferro, C.., Mark, P.., Kanbay, M.., Sarafidis, P.., Heine, G.., Rossignol, P.., Massy, Z.., Mallamaci, F.., Valdivielso, J.., Małyszko, J.., Verhaar, M.., Ekart, R.., Vanholder, R.., London, G.., Ortiz, A.., & Zoccali, C.. (2018). Lipid management in patients with chronic kidney disease. Nature Reviews Nephrology , 14 , 727-749 . http://doi.org/10.1038/s41581-018-0072-9
18) Gane, E.., Lawitz, E.., Pugatch, D.., Papatheodoridis, G.., Bräu, N.., Brown, A.., Pol, S.., Leroy, V.., Persico, M.., Moreno, Christophe., Colombo, M.., Yoshida, E.., Nelson, D.., Collins, Christine A.., Lei, Y.., Kosloski, M.., & Mensa, F.. (2017). Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. The New England Journal of Medicine , 377 , 1448–1455 . http://doi.org/10.1056/NEJMoa1704053
19) Hager, Matthew R.., Narla, A.., & Tannock, Lisa R. (2017). Dyslipidemia in patients with chronic kidney disease. Reviews in Endocrine and Metabolic Disorders , 18 , 29-40 . http://doi.org/10.1007/s11154-016-9402-z
20) Hager, Matthew R.., Narla, A.., & Tannock, Lisa R. (2017). Dyslipidemia in patients with chronic kidney disease. Reviews in Endocrine and Metabolic Disorders , 18 , 29-40 . http://doi.org/10.1007/s11154-016-9402-z
21) Hallan, S.., Matsushita, K.., Sang, Y.., Mahmoodi, B.., Black, C.., Ishani, A.., Kleefstra, N.., Naimark, David M J., Roderick, P.., Tonelli, M.., Wetzels, J.., Astor, B.., Gansevoort, R.., Levin, A.., Wen, C.., & Coresh, J.. (2012). Age and association of kidney measures with mortality and end-stage renal disease.. JAMA , 308 22 , 2349-60 . http://doi.org/10.1001/JAMA.2012.16817
22) Haynes, R.., Lewis, D.., Emberson, J.., Reith, C.., Agodoa, L.., Cass, A.., Craig, J.., Zeeuw, D. de., Feldt-Rasmussen, B.., Fellström, B.., Levin, A.., Wheeler, D.., Walker, R.., Herrington, W.., Baigent, C.., & Landray, M.. (2014). Effects of lowering LDL cholesterol on progression of kidney disease.. Journal of the American Society of Nephrology : JASN , 25 8 , 1825-33 . http://doi.org/10.1681/ASN.2013090965
23) Kanbay, M.., Solak, Y.., Unal, H.., Kurt, Y.., Gok, M.., Cetinkaya, H.., Karaman, M.., Oğuz, Y.., Eyileten, T.., Vural, A.., Covic, A.., Goldsmith, D.., Turak, O.., & Yılmaz, M.. (2014). Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. International Urology and Nephrology , 46 , 1619-1625 . http://doi.org/10.1007/s11255-014-0730-1
24) Kang, H.., Ahn, S.., Choi, Peter., Ko, Y.., Han, S.., Chinga, Frank., Park, Ae Seo Deok., Tao, Jianling., Sharma, K.., Pullman, J.., Bottinger, E.., Goldberg, I.., & Suszták, K.. (2014). Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nature Medicine , 21 , 37-46 . http://doi.org/10.1038/nm.3762
25) Kumar, A.., Palfrey, H. A.., Pathak, Rashmi., Kadowitz, P.., Gettys, T.., & Murthy, S. N.. (2017). The metabolism and significance of homocysteine in nutrition and health. Nutrition & Metabolism , 14 . http://doi.org/10.1186/s12986-017-0233-z
26) Kuo, C.., See, L.., Yu, Kuang-Hui., Chou, I.., Chiou, Meng‐Jiun., & Luo, S.. (2013). Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality.. Rheumatology , 52 1 , 127-34 . http://doi.org/10.1093/rheumatology/kes223
27) Lin, Zhuofeng., Zhou, Zhi-hong., Liu, Yanlong., Gong, Q.., Yan, Xinxin., Xiao, Jian., Wang, Xiaojie., Lin, Shao-qiang., Feng, Wenke., & Li, Xiaokun. (2011). Circulating FGF21 Levels Are Progressively Increased from the Early to End Stages of Chronic Kidney Diseases and Are Associated with Renal Function in Chinese. PLoS ONE , 6 . http://doi.org/10.1371/journal.pone.0018398
28) Merscher-Gomez, Sandra., Guzman, Johanna., Pedigo, C.., Lehto, M.., Aguillon-Prada, Robier., Mendez, A.., Lassenius, M.., Forsblom, C.., Yoo, T.., Villarreal, Rodrigo S.., Maiguel, D.., Johnson, Kevin., Goldberg, R.., Nair, V.., Randolph, Ann., Kretzler, M.., Nelson, R.., Burke, G.., Groop, P.., & Fornoni, A.. (2013). Cyclodextrin Protects Podocytes in Diabetic Kidney Disease. Diabetes , 62 , 3817 – 3827 . http://doi.org/10.2337/db13-0399
29) Mikolasevic, I.., Žutelija, M.., Mavrinac, V.., & Orlić, L.. (2017). Dyslipidemia in patients with chronic kidney disease: etiology and management. International Journal of Nephrology and Renovascular Disease , 10 , 35 – 45 . http://doi.org/10.2147/IJNRD.S101808
30) Mikolasevic, I.., Žutelija, M.., Mavrinac, V.., & Orlić, L.. (2017). Dyslipidemia in patients with chronic kidney disease: etiology and management. International Journal of Nephrology and Renovascular Disease , 10 , 35 – 45 . http://doi.org/10.2147/IJNRD.S101808
31) Mulay, S. R.., Evan, A.., & Anders, H.. (2014). Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association , 29 3 , 507-14 . http://doi.org/10.1093/ndt/gft248
32) Musso, G.., Cassader, M.., Cohney, S.., Michieli, Franco De., Pinach, S.., Saba, F.., & Gambino, R.. (2016). Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. Diabetes Care , 39 , 1830 – 1845 . http://doi.org/10.2337/dc15-1182
33) Papademetriou, V.., Lovato, L.., Tsioufis, C.., Cushman, W.., Applegate, W.., Mottle, Amy., Punthakee, Z.., Nylen, E.., & Doumas, M.. (2016). Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. American Journal of Nephrology , 45 , 136 – 145 . http://doi.org/10.1159/000453626
34) Penno, G.., Solini, A.., Bonora, E.., Fondelli, C.., Orsi, E.., Zerbini, G.., Trevisan, R.., Vedovato, M.., Gruden, G.., Cavalot, F.., Cignarelli, M.., Laviola, L.., Morano, S.., Nicolucci, A.., & Pugliese, G.. (2011). Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. Journal of Hypertension , 29 , 1802–1809 . http://doi.org/10.1097/HJH.0b013e3283495cd6
35) Saric, M.., & Kronzon, I.. (2011). Cholesterol embolization syndrome. Current Opinion in Cardiology , 26 , 472–479 . http://doi.org/10.1097/HCO.0b013e32834b7fdd
36) Silici, S.., Ekmekçioğlu, O.., Kanbur, M.., & Deniz, K.. (2011). The protective effect of royal jelly against cisplatin-induced renal oxidative stress in rats. World Journal of Urology , 29 , 127-132 . http://doi.org/10.1007/s00345-010-0543-5
37) Stadler, K.., Goldberg, I.., & Suszták, K.. (2015). The Evolving Understanding of the Contribution of Lipid Metabolism to Diabetic Kidney Disease. Current Diabetes Reports , 15 , 1-8 . http://doi.org/10.1007/s11892-015-0611-8
38) Syed-Ahmed, M.., & Narayanan, M.. (2019). Immune Dysfunction and Risk of Infection in Chronic Kidney Disease.. Advances in chronic kidney disease , 26 1 , 8-15 . http://doi.org/10.1053/j.ackd.2019.01.004
39) Tsai, Thomas., Patel, U.., Chang, T.., Kennedy, K.., Masoudi, F.., Matheny, M.., Kosiborod, M.., Amin, A.., Weintraub, W.., Curtis, J.., Messenger, J.., Rumsfeld, J.., & Spertus, J.. (2014). Validated Contemporary Risk Model of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights From the National Cardiovascular Data Registry Cath‐PCI Registry. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease , 3 . http://doi.org/10.1161/JAHA.114.001380
40) Udell, J.., Bhatt, Deepak L.., Braunwald, E.., Cavender, M.., Mosenzon, Ofri., Steg, P.., Davidson, J.., Nicolau, J.., Corbalán, R.., Hirshberg, B.., Frederich, R.., Im, K.., Umez-Eronini, A.., He, Ping., McGuire, D.., Leiter, Lawrence A., Raz, I.., & Scirica, B.. (2014). Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care , 38 , 696 – 705 . http://doi.org/10.2337/dc14-1850
41) Zhao, Ying-yong., Wang, Hui-Ling., Cheng, Xianlong., Wei, F.., Bai, Xu., Lin, R.., & Vaziri, N.. (2015). Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Scientific Reports , 5 . http://doi.org/10.1038/srep12936